Clinical evaluation of metastases of malignant melanoma imaging with99Tcm-glutathione and99Tcm-anti-melanoma antibody: A comparative study
Küçük Resim Yok
Tarih
1995
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
The aim of this investigation was to test for the scintigraphic detection of metastases of malignant melanoma with a new radiopharmaceutical,99Tcm-glutathione (99Tcm-GSH), in comparison with99Tcm- anti-melanoma antibody (99Tcm-AMAb). Glutathione was labelled with99Tcmby a Sn2+reduction method with an efficiency of > 99% as determined by instant thin layer chromatography (ITLC). Anti-melanoma antibody was obtained as a kit from SORIN (Italy) and labelled with99TcmO4. Forty-three patients with a total of 55 biopsy-proven metastatic melanoma foci, 1 ocular melanoma and 20 benign pathologic foci, also confirmed by ultrasound, computed tomography and magnetic resonance imaging, were included in the study after giving their informed consent. Following the intravenous (i.v.) injection of 500 MBq99Tcm-AMAb, scintigraphic images of the involved areas were obtained 6 h post-injection. Three days later, the same patients were given 500 MBq99Tcm-GSH i.v. and images were obtained 6 and 24 h post-injection. The images were classified as positive (focal abnormal accumulation) or negative. Quantitative evaluation was also applied. Regions of interest were drawn over the involved areas and nearby soft tissues and the target-to- nontarget (T/NT) ratios obtained with99Tcm-AMAb (T/NT: 1.92 ± 0.2) and99Tcm-GSH (T/NT: 1.84 ± 0.2) were compared (0.1 < P < 0.3). The sensitivity (and specificity) of99Tcm-AMAb and99Tcm-GSH in the detection of malignant melanoma metastases were 91% (95%) and 84% (90%), respectively. Compared with99Tcm-AMAb, the advantages of99Tcm-GSH are lower levels of blood radioactivity, lower costs and easy in-house preparation. In conclusion, our results show that99Tcm-GSH is a potentially useful radio-pharmaceutical for the detection of metastases of malignant melanoma. © 1995 Chapman and Hall Ltd.
Açıklama
Anahtar Kelimeler
Kaynak
Nuclear Medicine Communications
WoS Q Değeri
Scopus Q Değeri
N/A
Cilt
16
Sayı
11
